Raymond James Financial Inc. Acquires Shares of 53,626 Quanterix Co. (NASDAQ:QTRX)

Raymond James Financial Inc. acquired a new stake in shares of Quanterix Co. (NASDAQ:QTRX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 53,626 shares of the company’s stock, valued at approximately $570,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. FMR LLC increased its position in shares of Quanterix by 112.6% during the third quarter. FMR LLC now owns 30,242 shares of the company’s stock valued at $392,000 after buying an additional 16,020 shares during the period. State Street Corp boosted its position in Quanterix by 2.2% during the 3rd quarter. State Street Corp now owns 836,443 shares of the company’s stock valued at $10,840,000 after acquiring an additional 18,050 shares in the last quarter. Barclays PLC grew its holdings in shares of Quanterix by 42.3% during the 3rd quarter. Barclays PLC now owns 146,248 shares of the company’s stock worth $1,896,000 after acquiring an additional 43,447 shares during the period. Geode Capital Management LLC raised its position in shares of Quanterix by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 858,667 shares of the company’s stock worth $11,131,000 after acquiring an additional 18,231 shares in the last quarter. Finally, Empire Financial Management Company LLC lifted its stake in shares of Quanterix by 100.0% in the 3rd quarter. Empire Financial Management Company LLC now owns 37,500 shares of the company’s stock valued at $486,000 after purchasing an additional 18,750 shares during the period. Institutional investors own 86.48% of the company’s stock.

Analysts Set New Price Targets

QTRX has been the subject of a number of research reports. Canaccord Genuity Group decreased their price objective on Quanterix from $20.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, March 18th. Scotiabank reiterated an “outperform” rating on shares of Quanterix in a research note on Tuesday, March 25th.

Quanterix Stock Down 13.0 %

QTRX stock opened at $5.17 on Tuesday. The business’s 50-day moving average price is $7.57 and its 200-day moving average price is $10.33. The stock has a market cap of $200.47 million, a P/E ratio of -4.88 and a beta of 1.35. Quanterix Co. has a twelve month low of $4.87 and a twelve month high of $21.89.

Quanterix (NASDAQ:QTRX) last released its earnings results on Monday, March 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.03). The business had revenue of $35.16 million for the quarter, compared to analysts’ expectations of $34.93 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. On average, equities research analysts expect that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.